Lexeo Therapeutics (NASDAQ:LXEO) Receives Buy Rating from Chardan Capital
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. Several other brokerages also recently issued reports on LXEO. Royal Bank of Canada reissued an […]
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. Several other brokerages also recently issued reports on LXEO. Royal Bank of Canada reissued an […]
